Thomas H. Waid, MD

Medical Director, Renal and Pancreas Transplantation Program

Clinical interests

  • Acute Rejection Treatment
  • Continuous Renal Replacement Therapy
  • Critical Care Nephrology
  • Kidney and Pancreas Transplantation
  • Metabolic Bone Disease
  • Monoclonal Antibodies
  • Renal Failure

Thomas H. Waid, MD

Medical Director, Renal and Pancreas Transplantation Program

Biography

My name is Thomas H. Waid; I received my medical degree from the University of Kentucky, College of Medicine, Lexington. I completed a fellowship at the University of Kentucky, Lexington.

I am board certified by the American Board of Internal Medicine.

Podcasts

Faculty rank

Professor of Medicine

Education

Degree
University of Kentucky, College of Medicine, Lexington

Residency
University of Kentucky, Lexington

Fellowship
University of Kentucky, Lexington

Certifications or Special training
American Board of Internal Medicine

Nephrology, Bone & Mineral Metabolism

UK Good Samaritan Professional Arts Center
Suite 401
135 E. Maxwell St.
Lexington KY 40508-2640


UK HealthCare accepts many forms of insurance. See list of insurers »

 

Recent Publications

(Five most recent publications from PubMed via an automated list based on the provider’s ID and the University of Kentucky.)
  1. Waid TH, Thompson JS, Siemionow M, Brown SA.
    T10B9 monoclonal antibody: a short-acting nonstimulating monoclonal antibody that spares gammadelta T-cells and treats and prevents cellular rejection.
    Drug Des Devel Ther. 2009;3:205-12.
  2. Reddy KS, Stablein D, Taranto S, Stratta RJ, Johnston TD, Waid TH, McKeown JW, Lucas BA, Ranjan D.
    Long-term survival following simultaneous kidney-pancreas transplantation versus kidney transplantation alone in patients with type 1 diabetes mellitus and renal failure.
    Am J Kidney Dis. 2003 Feb;41(2):464-70.
  3. Reddy KS, Stablein D, Taranto S, Stratta RJ, Johnston TD, Waid TH, McKeown JW, Lucas BA, Ranjan D.
    Long-term survival following simultaneous kidney-pancreas transplantation versus kidney transplantation alone in patients with type 1 diabetes mellitus and renal failure.
    Transplant Proc. 33(1-2):1659-60.
  4. Waid TH, Thompson JS, McKeown JW, Brown SA, Sekela ME.
    Induction immunotherapy in heart transplantation with T10B9.1A-31: a phase I study.
    J Heart Lung Transplant. 1997 Sep;16(9):913-6.
  5. Waid TH, Lucas BA, Thompson JS, McKeown JW, Brown S, Kryscio R, Skeeters LJ.
    Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial.
    Transplantation. 1997 Jul 27;64(2):274-81.

View this provider on PubMed